WallStSmart

AbbVie Inc (ABBV)vsCorbus Pharmaceuticals Holding (CRBP)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

ABBV leads profitability with a 15.7% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 77/100 (B+).

ABBV

Strong Buy

77

out of 100

Grade: B+

Growth: 6.7Profit: 9.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

CRBP

Avoid

28

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-87.6%)

Margin of Safety

-87.6%

Fair Value

$157.25

Current Price

$294.64

$137.39 premium

UndervaluedFair: $157.25Overvalued

Intrinsic value data unavailable for CRBP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$520.47B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

EPS GrowthGrowth
2282.0%10/10

Earnings expanding 2282.0% YoY

Debt/EquityHealth
-17.6510/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.598/10

Growing faster than its price suggests

CRBP2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
50.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

CRBP4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$69.86M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 36.6%. Revenue growth of 10.3% demonstrates continued momentum.

Bull Case : CRBP

The strongest argument for CRBP centers on Price/Book, Debt/Equity.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.6x leaves little room for execution misses.

Bear Case : CRBP

The primary concerns for CRBP are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABBV profiles as a mature stock while CRBP is a value play — different risk/reward profiles.

CRBP carries more volatility with a beta of 2.79 — expect wider price swings.

ABBV is growing revenue faster at 10.3% — sustainability is the question.

ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (77/100 vs 28/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Corbus Pharmaceuticals Holding

HEALTHCARE · BIOTECHNOLOGY · USA

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.

Want to dig deeper into these stocks?